1. Ascl1 is required to specify a subset of ventromedial hypothalamic neurons.
- Author
-
Aslanpour S, Rosin JM, Balakrishnan A, Klenin N, Blot F, Gradwohl G, Schuurmans C, and Kurrasch DM
- Subjects
- Animals, Basic Helix-Loop-Helix Transcription Factors genetics, Cell Differentiation genetics, Cells, Cultured, Female, Gene Knockout Techniques, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Nerve Tissue Proteins genetics, Nerve Tissue Proteins metabolism, Neurogenesis genetics, Basic Helix-Loop-Helix Transcription Factors metabolism, GABAergic Neurons metabolism, Synaptic Transmission genetics, Ventromedial Hypothalamic Nucleus embryology, Ventromedial Hypothalamic Nucleus metabolism
- Abstract
Despite clear physiological roles, the ventromedial hypothalamus (VMH) developmental programs are poorly understood. Here, we asked whether the proneural gene achaete-scute homolog 1 ( Ascl1 ) contributes to VMH development. Ascl1 transcripts were detected in embryonic day (E) 10.5 to postnatal day 0 VMH neural progenitors. The elimination of Ascl1 reduced the number of VMH neurons at E12.5 and E15.5, particularly within the VMH-central (VMH
C ) and -dorsomedial (VMHDM ) subdomains, and resulted in a VMH cell fate change from glutamatergic to GABAergic. We observed a loss of Neurog3 expression in Ascl1-/- hypothalamic progenitors and an upregulation of Neurog3 when Ascl1 was overexpressed. We also demonstrated a glutamatergic to GABAergic fate switch in Neurog3 -null mutant mice, suggesting that Ascl1 might act via Neurog3 to drive VMH cell fate decisions. We also showed a concomitant increase in expression of the central GABAergic fate determinant Dlx1/2 in the Ascl1- null hypothalamus. However, Ascl1 was not sufficient to induce an ectopic VMH fate when overexpressed outside the normal window of competency. Combined, Ascl1 is required but not sufficient to specify the neurotransmitter identity of VMH neurons, acting in a transcriptional cascade with Neurog3 ., Competing Interests: Competing interestsD.M.K. is co-founder of Path Therapeutics, a start-up focused on anti-seizure drug discovery. The other authors declare no competing or financial interests., (© 2020. Published by The Company of Biologists Ltd.)- Published
- 2020
- Full Text
- View/download PDF